ERBB2 and breast carcinoma: Members of HER family take part in a complex array of combinatorial interactions through the formation of homo and heterodimers between the different family members and not only the preferred heterodimerization partner HER2, but also EGFR and recently HER3 have been defined as important therapeutic targets in breast cancer [6].